Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan.
Sunyoung KimHayeon LeeJin Seok LeeSeung-Won LeeRosie KwonMin Seo KimAi KoyanagiLee SmithGuillaume FondLaurent BoyerMasoud RahmatiGuillermo F López SánchezElena DragiotiSamuele CorteseJu-Young ShinAhhyung ChoiHae Sun SuhSunmi LeeMarco SolmiChanyang MinYoun Ho ShinDong-Keon YonPaolo Fusar-PoliPublished in: Nature human behaviour (2024)
We investigated whether SARS-CoV-2 infection is associated with short- and long-term neuropsychiatric sequelae. We used population-based cohorts from the Korean nationwide cohort (discovery; n = 10,027,506) and the Japanese claims-based cohort (validation; n = 12,218,680) to estimate the short-term (<30 days) and long-term (≥30 days) risks of neuropsychiatric outcomes after SARS-CoV-2 infection compared with general population groups or external comparators (people with another respiratory infection). Using exposure-driven propensity score matching, we found that both the short- and long-term risks of developing neuropsychiatric sequelae were elevated in the discovery cohort compared with the general population and those with another respiratory infection. A range of conditions including Guillain-Barré syndrome, cognitive deficit, insomnia, anxiety disorder, encephalitis, ischaemic stroke and mood disorder exhibited a pronounced increase in long-term risk. Factors such as mild severity of COVID-19, increased vaccination against COVID-19 and heterologous vaccination were associated with reduced long-term risk of adverse neuropsychiatric outcomes. The time attenuation effect was the strongest during the first six months after SARS-CoV-2 infection, and this risk remained statistically significant for up to one year in Korea but beyond one year in Japan. The associations observed were replicated in the validation cohort. Our findings contribute to the growing evidence base on long COVID by considering ethnic diversity.